Epanova    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病2

96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00613197
(ClinicalTrials.gov)
January 200315/1/2008EPANOVA in Crohn's Disease, Study 1A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.Crohn's DiseaseDrug: EpanovaTillotts Pharma AGNULLCompleted18 Years70 YearsBoth384Phase 3Belgium
2NCT00074542
(ClinicalTrials.gov)
September 200215/12/2003An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseA Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseCrohn's DiseaseDrug: Epanova™ (Omega-3 Free Fatty Acids)Tillotts Pharma AGNULLCompleted16 YearsN/ABoth364Phase 3United States;Canada